Table 2.

Ongoing clinical trials evaluating pazopanib in renal cell carcinoma.

Identifier	Phase	Description
NCT01566747	II	Sequential treatment of pazopanib in VEGF TKI refractory mRCC
NCT01157091	II	Sequential treatment of pazopanib in VEGF TKI refractory mRCC
NCT01684397	II	Combination study of pazopanib and bevacizumab
NCT01472081	II	Combination study of sunitinib, pazopanib or iplimumab, an anti-CTLA-4 antibody with nivolumab, an IgG4 antibody
NCT01521715	II	Single arm, pazopanib in poor-risk mRCC
NCT01392183	II	Pazopanib versus temsirolimus in poor-risk mRCC
NCT01538238	II	Single arm, pazopanib in non-clear-cell mRCC
NCT01361113	II	Single arm, pazopanib in neoadjuvant localized RCC
NCT01235962	III	Randomized, placebo-controlled study of pazopanib in high-risk localized RCC following nephrectomy

CTLA-4, cytotoxic T-lymphocyte antigen 4; IgG, immunoglobulin G; mRCC, metastatic renal cell carcinoma; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor; VEGF, vascular enothelial growth factor.